Thursday, March 13, 2014
Although the NIH
is taking preliminary steps to improve the reliability of preclinical data,
many researchers are not waiting for reproducibility guidelines and are taking
up the mantle to raise standards at their own institutions.
NIH is starting by testing ideas and introducing new procedures for its own
intramural scientists and grant review teams. The aim is to develop
recommendations for use by other institutions.
It takes a
to Tabak, the NIH initiative is not a reaction to political pressure and
instead is part of a community-wide response to a problem that involves many
Fishburn, C.S. SciBX 7(10); doi:10.1038/scibx.2014.275 Published
online March 13, 2014
1. Collins, F.S. & Tabak, L.A. Nature 505, 612-613
2. Prinz, F. et al. Nat. Rev. Drug Discov. 10, 712 (2011)
3. Begley, C.G. & Ellis, L.M. Nature 483, 531-533
4. Fulmer, T. SciBX 5(34);
5. Haas, M.J. SciBX 7(3);
Aldea Pharmaceuticals Inc., Redwood City, Calif.
American Association for the Advancement of Science, Washington, D.C.
(NASDAQ:AMGN), Thousand Oaks, Calif.
Bayer AG (Xetra:BAYN),
Global Biological Standards Institute, Washington, D.C.
National Institutes of Health, Bethesda, Md.
Nature Publishing Group, London, U.K.
Palo Alto, Calif.
Stanford University School of Medicine, Stanford, Calif.
The University of Texas MD Anderson Cancer Center, Houston, Texas